Allarity Therapeutics, Inc. cash flow statement

In fiscal 2025, Allarity Therapeutics, Inc.'s operations generated −$14.8m of cash; it spent $8,000 on capital projects, leaving free cash flow of −$14.8m. It returned $3.2m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Allarity Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Cash from operations	−17	−15
Depreciation and amortisation	0	—
Stock-based pay	0	0
Capital spending	0	0
Free cash flow	−18	−15
Free cash flow after stock pay	−18	−15
Share buybacks	0	3
Shares issued	37	11

US$ millions unless shown otherwise. Fiscal quarters.

Allarity Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−3	−5	−4	−3
Depreciation and amortisation	0	0	—	—
Stock-based pay	0	0	0	0
Capital spending	0	0	0	0
Free cash flow	−3	−5	−5	−3
Free cash flow after stock pay	−3	−6	−5	−3
Shares issued	11	0	0	0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Allarity Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Allarity Therapeutics, Inc.